Type your tag names separated by a space and hit enter

Inhibition of return (IOR) in patients with schizophrenia and cannabis use.

Abstract

Research concerning the spatial orientation in patients with schizophrenia has demonstrated a state independent deficit in inhibition of return (IOR), which has been discussed as a vulnerability marker for schizophrenia. Other recent investigations on brain structure and cognitive processing have revealed less deficits in schizophrenia patients with comorbid cannabis use (SCH + CUD) compared to abstinent schizophrenia patients (SCH). It was hypothesized that these results may reflect a premorbid lower vulnerability in at least a subgroup of comorbid patients. The aim of the present study is to extend previous work by investigating IOR functioning in patients with schizophrenia and cannabis use. This in turn should supplement the existing studies on the vulnerability of this patient group. Therefore, we compared IOR functioning in four groups: 62 patients with schizophrenia and 46 healthy controls, both with and without cannabis use. Participants underwent a covert orienting of attention task (COVAT) with peripheral cues and three stimulus onset asynchronies (SOAs: 200 ms, 400 ms and 800 ms). Both schizophrenia groups displayed delayed IOR with a more pronounced IOR effect in SCH + CUD compared to SCH. In healthy controls, IOR did not seem to be significantly affected by cannabis use. Significant IOR-differences between groups were only seen between SCH patients without cannabis use and both healthy groups at SOA 400 ms. Patterns of cannabis use as well as clinical parameters of psychoses did not affect IOR. Our results may support the hypothesis of IOR as a vulnerability marker for schizophrenia and of a lower biological vulnerability in at least a subgroup of SCH + CUD.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Medical School Hamburg, University of applied Science and Medical University, Department of Clinical Psychology and Psychotherapy, Am Kaiserkai 1, 20457 Hamburg, Germany. Electronic address: thomas.schnell@medicalschool-hamburg.de.

    ,

    Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland.

    ,

    Department of Psychiatry and Psychotherapy, University Hospital of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.

    Department of Psychiatry and Psychotherapy, LVR-Hospital Cologne, Wilhelm-Griesinger Str. 23, 51109 Cologne, Germany.

    Source

    MeSH

    Adult
    Attention
    Cannabis
    Comorbidity
    Female
    Humans
    Inhibition (Psychology)
    Male
    Marijuana Use
    Schizophrenia
    Schizophrenic Psychology

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    30184467

    Citation

    Schnell, Thomas, et al. "Inhibition of Return (IOR) in Patients With Schizophrenia and Cannabis Use." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 89, 2019, pp. 65-72.
    Schnell T, Heekeren K, Daumann J, et al. Inhibition of return (IOR) in patients with schizophrenia and cannabis use. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:65-72.
    Schnell, T., Heekeren, K., Daumann, J., & Gouzoulis-Mayfrank, E. (2019). Inhibition of return (IOR) in patients with schizophrenia and cannabis use. Progress in Neuro-psychopharmacology & Biological Psychiatry, 89, pp. 65-72. doi:10.1016/j.pnpbp.2018.09.001.
    Schnell T, et al. Inhibition of Return (IOR) in Patients With Schizophrenia and Cannabis Use. Prog Neuropsychopharmacol Biol Psychiatry. 2019 03 8;89:65-72. PubMed PMID: 30184467.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Inhibition of return (IOR) in patients with schizophrenia and cannabis use. AU - Schnell,Thomas, AU - Heekeren,Karsten, AU - Daumann,Jörg, AU - Gouzoulis-Mayfrank,Euphrosyne, Y1 - 2018/09/02/ PY - 2018/06/29/received PY - 2018/08/31/revised PY - 2018/09/01/accepted PY - 2018/9/6/pubmed PY - 2019/3/26/medline PY - 2018/9/6/entrez KW - Cannabis KW - Comorbidity KW - Inhibition of return (IOR) KW - Schizophrenia KW - Vulnerability SP - 65 EP - 72 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog. Neuropsychopharmacol. Biol. Psychiatry VL - 89 N2 - Research concerning the spatial orientation in patients with schizophrenia has demonstrated a state independent deficit in inhibition of return (IOR), which has been discussed as a vulnerability marker for schizophrenia. Other recent investigations on brain structure and cognitive processing have revealed less deficits in schizophrenia patients with comorbid cannabis use (SCH + CUD) compared to abstinent schizophrenia patients (SCH). It was hypothesized that these results may reflect a premorbid lower vulnerability in at least a subgroup of comorbid patients. The aim of the present study is to extend previous work by investigating IOR functioning in patients with schizophrenia and cannabis use. This in turn should supplement the existing studies on the vulnerability of this patient group. Therefore, we compared IOR functioning in four groups: 62 patients with schizophrenia and 46 healthy controls, both with and without cannabis use. Participants underwent a covert orienting of attention task (COVAT) with peripheral cues and three stimulus onset asynchronies (SOAs: 200 ms, 400 ms and 800 ms). Both schizophrenia groups displayed delayed IOR with a more pronounced IOR effect in SCH + CUD compared to SCH. In healthy controls, IOR did not seem to be significantly affected by cannabis use. Significant IOR-differences between groups were only seen between SCH patients without cannabis use and both healthy groups at SOA 400 ms. Patterns of cannabis use as well as clinical parameters of psychoses did not affect IOR. Our results may support the hypothesis of IOR as a vulnerability marker for schizophrenia and of a lower biological vulnerability in at least a subgroup of SCH + CUD. SN - 1878-4216 UR - https://www.unboundmedicine.com/medline/citation/30184467/Inhibition_of_return__IOR__in_patients_with_schizophrenia_and_cannabis_use_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(18)30503-7 DB - PRIME DP - Unbound Medicine ER -